Reporters.io
Amy Baxter
Pharma Voice
Profile
Contacts
Recent Articles on Subject
1
Amy Baxter
Pharma Voice
Scientist, inventor, former pediatrician.
Atlanta, Georgia
pain relief
technology
innovation
How Roche plans to fill a projected $8B sales gap
- 9 days ago
3 FDA approval dates to watch in the year’s final push
- 30 days ago
Lilly lays down $1B to be ‘first in biology’ with obesity gene therapies
- about 1 month ago
FDA adcomm reform talks heat up
- about 1 month ago
Pharma’s concerns pile up months after Supreme Court’s landmark Chevron decision
- about 2 months ago
BMS’ KarXT nears schizophrenia approval, but AbbVie and others wait in the wings
- about 2 months ago
The drugs hit hardest by Medicare price negotiations
- about 2 months ago
Can BioNTech sustain a post-COVID mRNA pipeline? Oncology is the next hope.
- about 2 months ago
A potential MS ‘game changer’ could bring more safety to the table — even against viruses
- about 2 months ago
M&A is ready to explode, and that’s good news for pharma layoffs
- about 2 months ago
Pharma execs react to final drug price negotiations with Medicare
- 2 months ago
Autobahn’s road to a breakthrough depression treatment is paved with high-profile investors
- 2 months ago
In a Duchenne market beset by problems, Capricor data marks a bright spot
- 2 months ago
Read to lead: 6 books pharma execs swear by
- 2 months ago
3 Big Pharma cancer drugs facing inflation penalties
- 2 months ago
Sage’s recent trial failure adds pressure to its two-drug Biogen collab
- 2 months ago
Where Kamala Harris stands on three key pharma issues
- 3 months ago
To overcome barriers, cell and gene therapies need outside support
- 3 months ago
Kyverna follows oncology’s CAR-T cell playbook for an ultra-rare autoimmune disorder
- 3 months ago
Is a better CAR-T cell therapy option on the horizon?
- 3 months ago
BMS’ long-standing leukemia blockbuster stares down its first generic
- 3 months ago
As the GLP-1 market booms, other healthcare companies are cashing in
- 3 months ago
The IRA will lower U.S. drug spending, CMS finds — but not for awhile
- 3 months ago
Will the real Ozempic please stand up? Lilly, Novo face uphill counterfeit battle
- 4 months ago
Ahead of its upcoming decision date, a competitor takes aim at KarXT
- 4 months ago
After an obesity deal with Novo, Omega’s new business head is on the hunt for more partners
- 4 months ago
The hunt for the brain’s biomarkers
- 4 months ago
Behind the powerful computations, AI’s role in pharma is still beset by challenges
- 4 months ago
FDA’s platform designation aims to ease R&D pain points
- 4 months ago
Behind Big Pharma’s layoffs — is there an end in sight?
- 4 months ago
Pfizer and Lilly are elbowing into the direct-to-consumer market. Will it work?
- 5 months ago
Execs from Bayer, Kite and Orca sound off on their launch strategies for cell and gene therapies
- 5 months ago
As AI proliferates in pharma, regulators look to catch up in clinical trials
- 5 months ago
4 offbeat biotechs making a splash in the life sciences
- 5 months ago
How a biotech exec is leveraging Big Pharma lessons to advance tRNA
- 5 months ago
What’s old is new: The revival of a one-time radiotherapy cancer treatment
- 6 months ago
Cutting pills. Rationing insulin. How Americans struggle to pay for drugs.
- 6 months ago
Women want to participate in clinical trials. Lack of flexibility is still a problem.
- 6 months ago
Next-gen menopause treatments have blockbuster potential. Can women, doctors and payers be convinced?
- 6 months ago
As antimicrobial resistance looms large, a nonprofit teams up with Big Pharma to intervene
- 6 months ago
To advance women’s leadership, an effort ‘has to be purposeful,’ says EMD Serono exec
- 6 months ago
To penetrate crowded GLP-1 field, Rivus Pharma is taking a metabolic approach
- 7 months ago
Takeda plots ‘unprecedented patient diversity’ for psoriasis drug that could compete with BMS
- 7 months ago
Why a pharmacist was tapped to spearhead ‘patient excellence’ at Boehringer Ingelheim
- 7 months ago
With historic MASH approval, Madrigal preps for launch and a public offering
- 7 months ago
5 Big Pharma CEOs who saw major pay bumps in 2023
- 7 months ago
These biotech hotspots are ripe for IPOs
- 7 months ago
COVID vaccine giants Moderna and Pfizer employ divergent tactics for the next chapter
- 7 months ago
Could pharma’s legal attack on the IRA succeed in killing price negotiations?
- 7 months ago
Did the FTC get it wrong when it blocked the Sanofi-Maze deal?
- 7 months ago